Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

NST NeuroSurvival Technologies Ltd. announced that the US Food and Drug Administration issued a 'safe to proceed' letter for the company's Aposense® [18F]-ML-10 investigational new drug application.

NST NeuroSurvival Technologies Ltd. (NST), a  clinical phase company developing molecular imaging agents and drugs that identify and target cells undergoing apoptosis (programmed cell death), announced that the US Food and Drug Administration (FDA) issued a 'safe to proceed' letter for the company's Aposense® [18F]-ML-10 Investigational New Drug Application (IND).

[18F]-ML-10 is a member of the Aposense family of molecules, a novel class of small molecular probes that detect and accumulate within cells undergoing apoptosis from its early stages. Apoptosis is a genetically-controlled process of cell death, associated with most medical disorders, in multiple clinical areas including oncology, neurology and cardiology. Upon recognizing apoptosis-specific changes on the cell membrane, Aposense molecules undergo a change enabling them to enter and accumulate within the dying cell from the early stages of the death process, while being excluded from viable or necrotic cells. The [18F]-ML-10 is labeled with the radioisotope 18F for molecular imaging of programmed cell death in 'real-time' with positron emission tomography (PET).

"This is a major step for our company as we now can expand our Aposense clinical program into the largest healthcare market in the world," said Yoram Ashery, CEO of NST NeuroSurvival Technologies. "Initial clinical data for our [18F]-ML-10 compound for molecular imaging of apoptosis suggest that we may be able to deliver on the promise of personalized medicine by using real-time images of cell death to monitor disease activity and patient response to treatment."

Pre-clinical studies with [18F]-ML-10 and other Aposense compounds showed selective uptake in apoptotic cells in a variety of disease models, including solid tumors undergoing radio- and chemo-therapy, different ischemic and inflammatory conditions, neuro-degenerative disorders, atherosclerosis, acute myocardial infarction and others.

A phase I clinical study conducted in Europe evaluated the safety, dosimetry and biodistribution of [18F]-ML-10 in normal healthy volunteers, and its suitability for imaging of cell death in the region of the infarct in patients with acute ischemic cerebral stroke. In both parts of the study, [18F]-ML-10 manifested an excellent safety profile and efficacy in imaging cell death. A phase IIa study was recently initiated in Israel in patients with metastatic brain tumors, a serious complication found in up to 25 per cent of patients with advanced cancer. The study evaluates [18F]-ML-10 in early assessment of response to radiotherapy, compared to MRI which typically can evaluate response only two months or longer after treatment has been completed.

Following the FDA's 'safe-to-proceed' letter for the [18F]-ML-10 IND, NST will expand its clinical programs in neurovascular disorders and cancer into the US. The first protocol already submitted to the FDA evaluates [18F]-ML-10 in visualizing apoptosis and neurovascular damage in patients with relapsing-remitting multiple sclerosis, as well as the safety of administering [18F]-ML-10. NST intends to submit additional protocols in the near term for evaluating [18F]-ML-10 in detecting and monitoring tumor response to anticancer therapy.